HCW BiologicsHCWB +1.86%39 Days Payable is 103,398.69 as of Mar. 2026, which is 5305% above its 10-year median of 1,912.87. GuruFocus rates HCWB with a GF Score™ of 39/100 and a GF Value™ of $7.29 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 708 Biotechnology companies, HCW Biologics ranks better than 98.87% on this metric.
The historical rank and industry rank for HCW Biologics's Days Payable or its related term are showing as below:
HCWB'
s Days Payable Range Over the Past 10 Years
Min: 63.98 Med: 1912.87 Max: 150562.5
Current: 116498.17
During the past 7 years, HCW Biologics's highest Days Payable was 150562.50. The lowest was 63.98. And the median was 1912.87.
HCWB's Days Payable is ranked better than 98.87% of 708
companies
in the Biotechnology industry
Industry Median: 113.56
vs HCWB: 116498.17
HCW Biologics's Days Payable
declined
from Mar. 2025 (479,815.31) to Mar. 2026 (103,398.69).
It may suggest that HCW Biologicsaccelerated paying its suppliers.
HCW Biologics Days Payable Related Terms
HCW Biologics Days Payable Historical Data
* Premium members only.
The historical data trend for HCW Biologics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, HCW Biologics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCW Biologics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HCW Biologics's Days Payable distribution charts can be found below:
* The bar in red indicates where HCW Biologics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
HCW Biologics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCW Biologics (HCWB) has a Days Payable of 103,398.69 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on HCW Biologics and its competitors. This is 5305% above median its historical median of 1,912.87. Over the past decade, HCW Biologics' Days Payable has ranged from 63.98 to 150,562.50. According to the industry distribution chart, HCW Biologics ranks #8 out of 708 companies in the Biotechnology industry, placing it in the top 1.1%.
Is HCW Biologics' Days Payable too high?
HCW Biologics' current Days Payable of 103,398.69 is 5305% above median its 10-year median of 1,912.87. Over the past 10 years, this metric has ranged from a low of 63.98 to a high of 150,562.50. The Biotechnology industry median Days Payable is 113.56. HCW Biologics' value of 103,398.69 is 90952% above this industry median. Based on the distribution chart, HCW Biologics ranks #8 out of 708 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HCW Biologics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' Days Payable compare to MTVA and INTI?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #8 out of 708 companies for Days Payable. This places HCW Biologics in the top 1% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. HCW Biologics' value of 103,398.69 is 90952% above this benchmark. Historically, HCW Biologics' own Days Payable has ranged from 63.98 to 150,562.50 over the past decade. While the company's 10-year median is 1,912.87 vs. the industry median of 113.56, HCW Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HCW Biologics's current Days Payable of 103,398.69 is 90952% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on HCW Biologics and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCW Biologics's current Days Payable is 103,398.69, which is 5305% above median its own 10-year median of 1,912.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $7.29, compared to a current price of $1.12 — trading 84.6% below its estimated fair value. The current Days Payable is 103,398.69, which is 5305% above median its 10-year median of 1,912.87 and 90952% above the Biotechnology industry median of 113.56. HCW Biologics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For HCW Biologics (HCWB), the current Days Payable is 103,398.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HCW Biologics (HCWB) Overvalued in 2026?
Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued.
The current stock price of $1.12 is trading 84.6% below its estimated GF Value™ of $7.29.
GuruFocus considers HCW Biologics to be Possible Value Trap.
Key valuation signals for HCWB:
Days Payable: 103,398.69 (5305% above median its 10-year median of 1,912.87)
GF Value™: $7.29 vs. price of $1.12 (84.6% below fair value)
Industry Position: 90952% above the Biotechnology median (#8 of 708)
No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score
Get the complete analysis for HCWB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCWB has been successfully added to your 
